title: Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation.
abstract: Silymarin prevents liver disease in many experimental rodent models, and is the most popular botanical medicine consumed by patients with hepatitis C. Silibinin is a major component of silymarin, consisting of the flavonolignans silybin A and silybin B, which are insoluble in aqueous solution. A chemically modified and soluble version of silibinin, SIL, has been shown to potently reduce hepatitis C virus (HCV) RNA levels in vivo when administered intravenously. Silymarin and silibinin inhibit HCV infection in cell culture by targeting multiple steps in the virus lifecycle. We tested the hepatoprotective profiles of SIL and silibinin in assays that measure antiviral and anti-inflammatory functions. Both mixtures inhibited fusion of HCV pseudoparticles (HCVpp) with fluorescent liposomes in a dose-dependent fashion. SIL inhibited 5 clinical genotype 1b isolates of NS5B RNA dependent RNA polymerase (RdRp) activity better than silibinin, with IC50 values of 40-85 µM. The enhanced activity of SIL may have been in part due to inhibition of NS5B binding to RNA templates. However, inhibition of the RdRps by both mixtures plateaued at 43-73%, suggesting that the products are poor overall inhibitors of RdRp. Silibinin did not inhibit HCV replication in subgenomic genotype 1b or 2a replicon cell lines, but it did inhibit JFH-1 infection. In contrast, SIL inhibited 1b but not 2a subgenomic replicons and also inhibited JFH-1 infection. Both mixtures inhibited production of progeny virus particles. Silibinin but not SIL inhibited NF-κB- and IFN-B-dependent transcription in Huh7 cells. However, both mixtures inhibited T cell proliferation to similar degrees. These data underscore the differences and similarities between the intravenous and oral formulations of silibinin, which could influence the clinical effects of this mixture on patients with chronic liver diseases.
authors.affiliation: Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America.
authors.forename: Jessica
authors.initials: J
authors.lastname: Wagoner
authors.forename: Chihiro
authors.initials: C
authors.lastname: Morishima
authors.forename: Tyler N
authors.initials: TN
authors.lastname: Graf
authors.forename: Nicholas H
authors.initials: NH
authors.lastname: Oberlies
authors.forename: Elodie
authors.initials: E
authors.lastname: Teissier
authors.forename: Eve-Isabelle
authors.initials: EI
authors.lastname: Pécheur
authors.forename: John E
authors.initials: JE
authors.lastname: Tavis
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Polyak
mesh_terms: D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D004333:Drug Administration Routes; D004339:Drug Compounding; D016174:Hepacivirus / Q000187:drug effects* / Q000254:growth & development; D006801:Humans; D000077385:Silybin; D012838:Silymarin / Q000008:administration & dosage*; D013601:T-Lymphocytes; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D012838:Silymarin; D000077385:Silybin